WaveMan
WaveMan · Company
WHWK · Whitehawk Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

WHWK Whitehawk Therapeutics (WHWK) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001422142
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
56
13F, latest reported quarter

Whitehawk Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Whitehawk Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Giacobello Scott M.
CHIEF FINANCIAL OFFICER
SELL
2026-04-17 SECtraded 2026-04-16
141,600
$584.8K
-21.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 15, 2026.
  • The trade is 48.0% of the 295,224 shares held after it.
  • 2 other insiders sold within 30 days.
  • 56 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Giacobello Scott M. sold about $584.8K of WHWK on Apr 16, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 56 funds added in the latest 13F quarter.
Giacobello Scott M.
CHIEF FINANCIAL OFFICER
SELL
2026-04-17 SECtraded 2026-04-15
77,000
$297.2K
-21.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 2, 2026.
  • The trade is 17.6% of the 436,824 shares held after it.
  • 2 other insiders sold within 30 days.
  • 56 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Giacobello Scott M. sold about $297.2K of WHWK on Apr 15, 2026; 2 other insiders sold within 30 days and 56 funds added in the latest 13F quarter.
BALL BRYAN
See remarks
SELL
2026-04-15 SECtraded 2026-04-14
92,460
$336.6K
-21.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Apr 13, 2026.
  • The trade is 23.3% of the 397,106 shares held after it.
  • 2 other insiders sold within 30 days.
  • 56 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See remarks BALL BRYAN sold about $336.6K of WHWK on Apr 14, 2026; 2 other insiders sold within 30 days and 56 funds added in the latest 13F quarter.
BALL BRYAN
See remarks
SELL
2026-04-15 SECtraded 2026-04-13
26,389
$91.3K
-21.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Apr 10, 2026.
  • The trade is 5.4% of the 489,566 shares held after it.
  • 2 other insiders sold within 30 days.
  • 56 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See remarks BALL BRYAN sold about $91.3K of WHWK on Apr 13, 2026; 2 other insiders sold within 30 days and 56 funds added in the latest 13F quarter.
BALL BRYAN
See remarks
SELL
2026-04-13 SECtraded 2026-04-10
6,596
$22.6K
-16.8%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 9, 2026.
  • The trade is 1.3% of the 515,955 shares held after it.
  • 2 other insiders sold within 30 days.
  • 56 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See remarks BALL BRYAN sold about $22.6K of WHWK on Apr 10, 2026; 2 other insiders sold within 30 days and 56 funds added in the latest 13F quarter.
14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 9 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
56 funds bought in last quarter
below 51% of Pharma & Biotech
Revenue
-72.5% year over year
below 86% of Pharma & Biotech
Margin
-288.3% net margin
below 71% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
9.4% of the float short (float per yahoo 2026-10-26) · 7.1 days to cover · settled 2026-09-30
below 51% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch WHWK

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+35.9%12M
-19%+24%+66%+108%2025-102025-122026-022026-042026-062026-082026-10 2026-04-16 · Giacobello Scott M. sold $584.8K2026-04-06 · Lennon David James sold $359.4K2026-04-14 · BALL BRYAN sold $336.6K2026-04-07 · Lennon David James sold $322.7K2026-04-15 · Giacobello Scott M. sold $297.2K2026-04-08 · Lennon David James sold $217.4K2026-04-09 · BALL BRYAN sold $178.5K2026-04-02 · Lennon David James sold $93.5K2026-04-13 · BALL BRYAN sold $91.3K2026-04-09 · Lennon David James sold $49.0K2026-04-10 · BALL BRYAN sold $22.6K2026-03-02 · Lennon David James sold $16.9K2026-03-02 · Giacobello Scott M. sold $8.6K2026-03-02 · BALL BRYAN sold $6.1K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns WHWK: institutional holders (13F)

13F holdings, latest reported quarter
Yu Fan
4,861,314 sh
$22.3M
ACUTA CAPITAL PARTNERS, LLC
4,685,912 sh
$21.5M
QVT Financial LP
4,615,709 sh
$21.1M
MONTANOVA CAPITAL, LLC
4,300,000 sh
$19.7M
ORBIMED ADVISORS LLC
3,934,296 sh
$18.0M

Congress trades in WHWK

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

WHWK planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

WHWK mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$757.0K position · as of 2026-06-30
0.8%
iShares Micro-Cap ETF
$506.4K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$33.8K position · as of 2026-06-30
0.0%
Fidelity Small Cap Value Index Fund
$206.4K position · as of 2026-06-30
0.0%
iShares Russell 2000 Value ETF
$1.3M position · as of 2026-06-30
0.0%
PD Small-Cap Value Index Portfolio
$8.0K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · David Lennon
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.4M
$4.5M
$2.0M
-81%
n/a
2024
$1.0M
$1.6M
$1.2M
-75%
n/a
2022
$3.1M
n/a
$1.6M
-47%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 56 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

WHWK financials

Revenue growth
-72.5%
XBRL, annual
Net margin
-288.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$69.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-45.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-42.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-48.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-36.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$7.1M$26.0M$24.4M$15.2M
Operating income-$114.4M-$67.5M-$71.9M-$62.7M
Net income-$20.6M-$63.7M-$65.8M-$60.5M
EPS (diluted)-0.33-2.36-2.44-2.69
Operating cash flow-$97.4M-$59.5M-$59.7M-$49.6M
Cash$37.6M$28.7M$62.9M$39.0M
Dividends paidn/an/an/a$0
SEC XBRL, fiscal years, as known on 2026-10-28

WHWK Stock Sonar score 4/7 axes

Find similar shapesCompare

WHWK ranks highest on risk and compliance (62nd percentile) and profitability (53rd), and lowest on growth (14th), among Pharma & Biotech peers.

Profitability
53
Inputs
  • Return on equity-45.0% · 58 pct, sector of 545
  • Return on assets-42.6% · 50 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-48.5% · 52 pct, sector of 576
Growth
14
Inputs
  • Revenue growth, YoY-72.5% · 14 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
49
Inputs
  • Funds adding, latest quarter56 · 49 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
62
Inputs
  • Short interest, % of float+9.4% · 41 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+4.7% · 84 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies